Clinical Trial Update: Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating combination of Lanreotide Autogel 120mg with Temozolomide in progressive gastroenteropancreatic neuroendocrine tumors has completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• Lanreotide Autogel (lanreotide)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Ipsen | Conditions: Gastroenteropancreatic Neuroendocrine Tumors | Phase 2 | Status: COMPLETED | Results posted: 2019-05-06